Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance subcutaneous rituximab after rescue R-GemOxD in relapsed/refractory mantle cell lymphoma
2014-001911-38Phase 2Completed
- Sponsor
- GELTAMO
- Start
- Aug 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in mantle cell lymphoma (MCL), sponsored by GELTAMO. Primary endpoint: Time to relapse/progression (TTP). Started Aug 2014; status: completed.
02
Drugs
rituximab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2014-001911-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001911-38.